<div id="readability-page-1"><div> By Josh Beckerman <pre></pre> Broadwood Partners, which owns 27.3% of Staar Surgical, said it intends to vote against the lens company's sale to Alcon, citing issues related to the sale process and its belief in Staar's growth potential. Broadwood said Tuesday that Staar didn't pursue an adequate sale process and there was &#34;intransigence with respect to the process regarding Broadwood's books and records demand.&#34; Staar said the deal provides &#34;compelling, premium cash value,&#34; including a 51% premium to its Aug. 4 closing price. &#34;We believe the $28-per-share cash value provided by the Alcon agreement exceeds what STAAR could achieve on a standalone basis in the foreseeable future, particularly given STAAR's lower growth rate and the resulting impact on its valuation, and the substantial competitive and macro challenges in the markets STAAR serves,&#34; the company said. &#34;STAAR is heavily exposed to China, which faces significant economic uncertainty and where sales trends have been declining despite actions taken by the company,&#34; Staar said. The Alcon deal includes provisions that are highly favorable to Staar stockholders and were extensively negotiated, it said. <pre></pre> Write to Josh Beckerman at josh.beckerman@wsj.com <pre></pre> (END) Dow Jones Newswires September 02, 2025 19:07 ET (23:07 GMT)Copyright (c) 2025 Dow Jones &amp; Company, Inc.</div></div>

爱尔康

达视光学

Broadwood Partners 持有达视光学 27.3% 的股份，计划投票反对该公司出售给爱尔康，理由是对出售过程和达视光学的增长潜力表示担忧。他们认为达视光学没有充分追求出售，并且在获取记录方面面临问题。达视光学为这笔交易辩护，强调其最近收盘价的 51% 溢价，并声称每股 28 美元的报价超过了潜在的独立价值，尽管市场面临挑战，特别是在中国

Broadwood Partners 计划投票反对将 STAAR Surgical 出售给 Alcon